Significant Association of Metabolic Indices, Lipid Profile, and Androgen Levels with Prostate Cancer |
Tewari, Reshu
(Department of Pathology, King George's Medical University)
Chhabra, Mohini (Central Drug Research Institute (CSIRCDRI)) Natu, Shankar Madhavan (Department of Pathology, King George's Medical University) Goel, Apul (Department of Urology, King George's Medical University) Dalela, Divakar (Department of Urology, King George's Medical University) Goel, Madhu Mati (Central Drug Research Institute (CSIRCDRI)) Rajender, Singh (Central Drug Research Institute (CSIRCDRI)) |
1 | Brawley OW (2003). Hormonal prevention of prostate cancer. Urol Oncol, 21, 2167-72. |
2 | Burke JP, Rhodes T, Jacobson DJ, et al (2006). Association of anthropometric measures with the presence and progression of benign prostatic hyperplasia. Am J Epidemiol, 164, 41-6. DOI ScienceOn |
3 | Center MM, Jemal A, Lortet-Tieulent J, et al (2012). International variation in prostate cancer incidence and mortality rates. Eur Urol, 61, 1079-92. DOI ScienceOn |
4 | Clarke NW1, Hart CA, Brown MD (2009). Molecular mechanisms of metastasis in prostate cancer. Asian J Andro, 11, 57-67. DOI |
5 | Clarke WN, Brown DM (2007). The Influence of Lipid Metabolism on Prostate Cancer Development and Progression: Is it Time for a Closer Look? Euro Urol, 52, 3-4. DOI |
6 | Dandona P, Weinstock R, Thus k, et al (1998). Tumor necrosis factor -, in sera of obese patients fall with weight loss. J Clin Endocrinol Metab, 83, 2907-10. |
7 | Garfinkel L (1986). Overweight and mortality. Cancer, 58, 1826-29. DOI |
8 | Gillitzer R, Pahernik S, Hampelc (2005). Relationship between prostate cancer and serum dyslipidemia. Urology, 66, 13-14. |
9 | Giovannucci E, Stampfer MJ, Krithivas K, et al (1997). The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A, 94, 3320-23. DOI ScienceOn |
10 | Girling JF, Whitaker HC, Mills IG (2007). Pathogenesis of prostate cancer and hormone refractory prostate cancer. Indian J Urol, 23, 35-42. DOI |
11 | Gupta A, Gupta S, Pavuk M, Roehrborn CG (2006). Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology, 68, 1198-205. DOI ScienceOn |
12 | Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D (1998). Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis, 3, 157-62. |
13 | Hsing AW, Sakoda LC, Chua SC (2007). Obesity, metabolic syndrome, and prostate cancer. Amer J Clin Nutr, 86, 843-57. |
14 | Jaradeen, N (2010). Breast cancer risk-factors and breast self examination practice among Jordanian women. Bahrain Med Bulletin, 32, 1 |
15 | Lekili M, Muezzinoglu T, Uyanik BS, Buyuksu C (2006). Serum lipid levels in benign prostatic hyperplasia. World J Urol, 24, 210-3. DOI ScienceOn |
16 | Long XJ, Lin S, Sun YN, Zheng ZF (2012). Diabetes mellitus and prostate cancer risk in Asian countries: a meta-analysis. Asian Pac J Cancer Prev, 13, 4097-100. 과학기술학회마을 DOI ScienceOn |
17 | McGrowder DA, Jackson LA, Crawford TV (2012). Prostate cancer and metabolic syndrome: is there a link? Asian Pac J Cancer Prev, 13, 1-13. 과학기술학회마을 DOI ScienceOn |
18 | Mitropoulos D, Ploumidou K, Voulgari K (2003) Hypercholesterol diet alters serum lipid profile and ventral prostate structure in rats. Eur Urol Suppl, 63, 2-20. |
19 | Nandeesha H, Koner BC, Dorairajan LN, Sen SK (2006). Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clinica Chimica Acta, 370, 89-93. DOI |
20 | Nomura AM, Kolonel LN (1991). Prostate cancer: a current perspective. Epidemiol Rev, 13, 200-27. |
21 | Ozbek E, Otunctemur A, Dursun M, et al (2014). The metabolic syndrome is associated with more aggressive prostate cancer. Asian Pac J Cancer Prev, 15, 4029-32. 과학기술학회마을 DOI ScienceOn |
22 | Pandeya DR, Mittal A, Sathian B, Bhatta B (2014). Role of hyperinsulinemia in increased risk of prostate cancer: a case control study from Kathmandu Valley. Asian Pac J Cancer Prev, 15, 1031-3. 과학기술학회마을 DOI ScienceOn |
23 | Parsons JK, Bergstrom J, Barrett CE (2008). Lipids, Lipoproteins and Risk of benign prostatic hyperplasia in communitydwelling Men. BJU Int, 101, 313-8. DOI ScienceOn |
24 | Platz EA, Leitzmann MF, Visvanathan K, et al (2006). Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst, 98, 1819-25. DOI ScienceOn |
25 | Prabhat P, Tewari R, Natu SM, et al (2010). Is central obesity, hyperinsulinemia, and dyslipidemia associated with highgrade prostate cancer? A descriptive cross-sectional study. Ind J Uro, 26, 502-6. DOI |
26 | Stephen JF, Brady JB (2005). Obesity and prostate cancer: a growing problem. Clin Cancer Res, 11, 6763-6. DOI |
27 | Tewari R, Prabhat P, Natu SM, et al (2011). Association of benign prostatic hyperplasia (BPH) with metabolic syndrome (MS) and its components: A growing dilemma. J Men's Health, 8, 66-71. DOI |
28 | Tewari R, Rajender S, Natu SM, et al (2012). Diet, obesity, and prostate health: are we missing the link? J Andro, 33, 763-76 DOI ScienceOn |
29 | Wuermli L, Joerger M, Henz S, et al (2005). Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis, 8, 316-20. DOI ScienceOn |
30 | Tewari R, Rajender S, Natu SM, et al (2013). Significance of obesity markers and adipocytokines in high grade and high stage prostate cancer in North Indian men - a cross-sectional study. Cytokine, 10, 130-4. |
31 | Zeigler-Johnson CM, Walker AH, Mancke B et al (2002). Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered, 54, 13-21. DOI |
32 | Zhang Q, Sun LJ, Qi J, Yang ZG, Huang T (2014). Influence of adipocytokines and periprostatic adiposity measurement parameters on prostate cancer aggressiveness. Asian Pac J Cancer Prev, 15, 1879-83. 과학기술학회마을 DOI |
33 | Zucchetto A, Tavani A, Dal ML, et al (2005). A history of weight and obesity through life and risk of benign prostatic hyperplasia. Int J Obes, 29, 798-803. DOI |